Ridwan Alam, MD, a urology resident at Johns Hopkins Brady Urological Institute, discusses how determining the reason for survival differences between difference races requires an in-depth examination of both genetic and socioeconomic factors. Alam, presented the abstract, “Investigation of race and associated socioeconomic factors in survival outcomes for patients with renal cell carcinoma,” which he presented at the 2022 AUA Annual Meeting (abstract PD18-12).
Toripalimab plus axitinib approved in China for renal cell carcinoma
April 11th 2024The approval is based on findings from the phase 3 RENOTORCH trial, which showed that toripalimab plus axitinib prolonged progression-free survival and improved the objective response rate in patients with advanced RCC compared with sunitinib.